Psoriatic Arthritis

More than half of patients with psoriatic arthritis have to wait two or more years for a diagnosis, researchers report.

Many patients with psoriatic arthritis live with unacceptable levels of disease activity despite treatment, and patient-reported outcomes could provide useful treatment targets, shows a new study.

In patients with psoriatic arthritis who are DMARD naïve, ixekizumab had similar efficacy at one year whether it was used as a monotherapy or in combination with methotrexate or csDMARD, while adalimumab showed better efficacy as a combination therapy.

Favorable phase 2 results with the TYK2 inhibitor for psoriatic arthritis at ACR 2020 coincided with announced positive phase 3 trial results for psoriasis.

In a study that examined the effects of guselkumab (Tremfya, Janssen) on fatigue in patients with psoriatic arthritis, the treatment reduced fatigue through one year, according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

Patients with inflammatory arthritis and osteoarthritis should be participating in four different types of exercise: cardiovascular, strength, flexibility, and balance. But a new study shows that patients are overly focused on cardiovascular exercise and not enough on exercise types designed to strengthen and protect joints and bones.

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.

This approval makes the drug the first of its kind to treat polyarticular juvenile idiopathic arthritis and psoriatic arthritis in a pediatric population.

The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​